These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9158879)

  • 1. Pharmacokinetic stereoselectivity of troglitazone, an antidiabetic agent, in the KK mouse.
    Izumi T; Enomoto S; Hoshiyama K; Sasahara K; Sugiyama Y
    Biopharm Drug Dispos; 1997 May; 18(4):305-24. PubMed ID: 9158879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data.
    Izumi T; Hosiyama K; Enomoto S; Sasahara K; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1392-400. PubMed ID: 9067328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of protein binding of troglitazone stereoisomers by fluorometric titration.
    Izumi T; Hoshiyama K; Enomoto S; Sasahara K; Sugiyama Y
    Biopharm Drug Dispos; 1997 Apr; 18(3):241-57. PubMed ID: 9113346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs.
    Kawai K; Kawasaki-Tokui Y; Odaka T; Tsuruta F; Kazui M; Iwabuchi H; Nakamura T; Kinoshita T; Ikeda T; Yoshioka T; Komai T; Nakamura K
    Arzneimittelforschung; 1997 Apr; 47(4):356-68. PubMed ID: 9150855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045.
    Yoshioka T; Aizawa Y; Fujita T; Nakamura K; Sasahara K; Kuwano H; Kinoshita T; Horikoshi H
    Chem Pharm Bull (Tokyo); 1991 Aug; 39(8):2124-5. PubMed ID: 1797433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats.
    Michels GM; Boudinot FD; Ferguson DC; Hoenig M
    Am J Vet Res; 2000 Jul; 61(7):775-8. PubMed ID: 10895899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency.
    Ott P; Ranek L; Young MA
    Eur J Clin Pharmacol; 1998 Sep; 54(7):567-71. PubMed ID: 9832300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.
    Loi CM; Randinitis EJ; Vassos AB; Kazierad DJ; Koup JR; Sedman AJ
    J Clin Pharmacol; 1997 Dec; 37(12):1114-20. PubMed ID: 9506006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach.
    Izumi T; Enomoto S; Hosiyama K; Sasahara K; Shibukawa A; Nakagawa T; Sugiyama Y
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1630-41. PubMed ID: 8667232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites.
    Loi CM; Alvey CW; Randinitis EJ; Abel R; Young MA; Koup JR
    J Clin Pharmacol; 1997 Nov; 37(11):1038-47. PubMed ID: 9505997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice.
    Fujiwara T; Okuno A; Yoshioka S; Horikoshi H
    Metabolism; 1995 Apr; 44(4):486-90. PubMed ID: 7723671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.
    Kassahun K; Pearson PG; Tang W; McIntosh I; Leung K; Elmore C; Dean D; Wang R; Doss G; Baillie TA
    Chem Res Toxicol; 2001 Jan; 14(1):62-70. PubMed ID: 11170509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
    Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal absorption and excretion of troglitazone sulphate, a major biliary metabolite of troglitazone.
    Kawai K; Hirota T; Muramatsu S; Tsuruta F; Ikeda T; Kobashi K; Nakamura KI
    Xenobiotica; 2000 Jul; 30(7):707-15. PubMed ID: 10963061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troglitazone.
    Spencer CM; Markham A
    Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and pharmacokinetic studies of the newly synthesized thiazolidinedione derivative 5-(4-(1-phenyl-1-cyclopropanecarbonylamino)benzyl)-thiazolidine-2 ,4-dio ne.
    Ueda N; Nomura Y; Muta Y; Matsuzaki Y; Hayashibe M; Ino Y; Suzuki S; Kurumi M
    Arzneimittelforschung; 1998 Jun; 48(6):651-7. PubMed ID: 9689422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone: an antidiabetic agent.
    Chen C
    Am J Health Syst Pharm; 1998 May; 55(9):905-25. PubMed ID: 9588250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical property of troglitazone, an equal mixture of four stereoisomers.
    Suzuki N; Kasahara K; Hasegawa H; Kawasaki T
    Int J Pharm; 2002 Nov; 248(1-2):71-80. PubMed ID: 12429461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of troglitazone stereoisomers in rat plasma using semi-micro HPLC with electrochemical detection.
    Suzuki N; Miyashita N; Kotani A; Kusu F; Kawasaki T
    J Pharm Biomed Anal; 2005 Jun; 38(1):155-61. PubMed ID: 15907634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant administration of cholestyramine influences the absorption of troglitazone.
    Young MA; Lettis S; Eastmond R
    Br J Clin Pharmacol; 1998 Jan; 45(1):37-40. PubMed ID: 9489592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.